Viatris (VTRS) Cash & Equivalents (2019 - 2026)
Viatris (VTRS) posted quarterly Cash & Equivalents of $1.8 billion for Q1 2026, up 138.97% year-over-year from $755.0 million in Q1 2025, and up 36.43% quarter-over-quarter from $1.3 billion in Q4 2025.
Viatris (VTRS) Cash & Equivalents (2019 - 2026) Analysis & Trends
Viatris' Cash & Equivalents history runs 8 years deep, the most recent figure standing at $1.8 billion for Q1 2026.
- In Q1 2026, Cash & Equivalents rose 138.97% year-over-year to $1.8 billion; the TTM figure through Mar 2026 stood at $1.8 billion (up 138.97% YoY), while the FY2025 annual figure was $1.3 billion, up 79.65% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $1.8 billion, up from $1.3 billion in the prior quarter.
- The five-year high for Cash & Equivalents was $1.9 billion in Q3 2024, with the low at $506.6 million in Q1 2023.
- The 5-year median for Cash & Equivalents is $917.2 million (2024), against an average of $984.3 million.
- The sharpest annual moves came in 2025 and 2026: Cash & Equivalents sank 48.09% in 2025, then jumped 138.97% in 2026.
- Viatris' Cash & Equivalents stood at $1.3 billion in 2022, then dropped by 21.43% to $991.9 million in 2023, then fell by 25.79% to $736.1 million in 2024, then soared by 79.65% to $1.3 billion in 2025, then surged by 36.43% to $1.8 billion in 2026.
- Business Quant data shows VTRS's Cash & Equivalents at $1.8 billion in Q1 2026, $1.3 billion in Q4 2025, and $975.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | 1.11 Bn |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 1.48 Bn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 2.89 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 1.80 Bn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 332.40 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | 164.00 Mn |
| 10 | Alkermes | 8.21 Bn | 7.55 Bn | 397.90 Mn | 511.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 886.50 Mn |
| Mar 31, 2026 | 1.80 Bn |
| Dec 31, 2025 | 1.32 Bn |
| Sep 30, 2025 | 975.30 Mn |
| Jun 30, 2025 | 566.40 Mn |
| Mar 31, 2025 | 755.00 Mn |
| Dec 31, 2024 | 736.10 Mn |
| Sep 30, 2024 | 1.88 Bn |
| Jun 30, 2024 | 917.20 Mn |
| Mar 31, 2024 | 1.01 Bn |
| Dec 31, 2023 | 991.90 Mn |
| Sep 30, 2023 | 1.31 Bn |
| Jun 30, 2023 | 629.20 Mn |
| Mar 31, 2023 | 506.60 Mn |
| Dec 31, 2022 | 1.26 Bn |
| Sep 30, 2022 | 646.70 Mn |
| Jun 30, 2022 | 664.70 Mn |
| Mar 31, 2022 | 752.40 Mn |
| Dec 31, 2021 | 706.20 Mn |
| Sep 30, 2021 | 756.60 Mn |